Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Taiho to Terminate Multinational PIII Study of Angiogenesis Inhibitor Orantinib for Hepatocellular Carcinoma
August 4, 2014
- Daiichi Sankyo to Transfer Akita Plant to Alfresa Pharma
August 4, 2014
- Kyowa Kirin, AstraZeneca Hook Up in Immuno-Oncology Clinical Study
August 1, 2014
- Kyowa Kirin Taking Nesp Issue Seriously from Ethical Standpoint: Pres.
August 1, 2014
- Anticancer Agent Lenvatinib Granted EMA Accelerated Review: Eisai
August 1, 2014
- Kyowa Kirin to Outsource Sales of Recombinant Human Antithrombin Preparation to JB
August 1, 2014
- Takara Bio to Buy Swedish Stem Cell Company
July 31, 2014
- Kyowa Kirin’s Half-Year Pharma Operating Profit Tumbles 41% on Price Cuts
July 31, 2014
- Nissan Chemical Files Livalo Patent Suit against Sawai in US
July 31, 2014
- Sanofi Files NDA for HOE901-U300, Successor Drug to Lantus, in Japan
July 31, 2014
- LSI Medience, Kyushu TLO Jointly Set Up KPSL, New Business Entity in Clinical Laboratory Test Field
July 31, 2014
- Kyowa Kirin Begins PI Study for XLH Adult Patients in Japan, South Korea
July 30, 2014
- Alfresa Group Companies Tokiwa Yakuhin and Seiwa Sangyo to Merge
July 30, 2014
- Meiji Seika Pharma Licenses Opalmon from Ono for Its Commercialization in Thailand and Indonesia
July 29, 2014
- AbbVie Hopes to Make Humira Major Drug for Biologics-Naïve Patients: President
July 28, 2014
- New Guidelines for Investigator-Led Trials to Take Effect at August-End: Novartis Japan
July 28, 2014
- Januvia Ranked No.1 in GP Market in June: Anterio’s “Mind Share” Ranking
July 28, 2014
- TS-1 Fails to Meet Primary Endpoint in PIII Study in Japan for Advanced Hepatocellular Carcinoma: Taiho
July 28, 2014
- Chugai Half-Year Earnings Upbeat on Actemra; Anti-PCSK9 Drug Ditched from Pipeline
July 25, 2014
- Kyowa Kirin Launches PII Study for XLH Drug KRN23 in US, Europe
July 25, 2014
ページ
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…